S

    SLNO (SLNO)

    Official site

    BIOTECHNOLOGY

    $53.01
    +0.00 (+0.00%)

    Last updated: May 19, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    +14.73%

    Upcoming Estimates

    Jun 30, 2026
    EPS Consensus$0.93
    Range$0.78 - $1.26
    8 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$0.98+4.9%
    60d ago$0.94+0.6%
    30d ago$0.94+0.4%
    7d ago$0.94+0.4%
    Current$0.93
    Revenue Consensus
    $112M
    Range$106M - $120M
    7 analysts
    Sep 30, 2026
    EPS Consensus$1.06
    Range$0.78 - $1.55
    8 analysts
    EPS RevisionsNo revisions (7d)
    0
    4
    30d
    EPS Estimate Drift
    90d ago$1.13+6.2%
    60d ago$1.05-1.3%
    30d ago$1.06+0.0%
    7d ago$1.06+0.0%
    Current$1.06
    Revenue Consensus
    $123M
    Range$116M - $134M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.22---
    Sep 26EST
    		-$1.06---
    Jun 26EST
    		-$0.93---
    Mar 26
    		$0.59$0.68-13.24%Miss+162.1%
    Dec 25
    		$0.80$0.21+272.09%Beat+163.0%
    Sep 25
    		$0.47$0.05+840.00%Beat+125.7%
    Jun 25
    		$-0.09N/A+85.94%Beat+84.2%
    Mar 25
    		$-0.95$-0.93-2.43%Miss-61.0%
    Dec 24
    		$-1.27$-1.08-17.91%Miss-284.8%
    Sep 24
    		$-1.83$-0.63-190.48%Miss-92.6%
    Jun 24
    		$-0.57$-0.60+5.00%Beat+29.6%
    Mar 24
    		$-0.59$-0.37-59.46%Miss+33.0%
    Dec 23
    		$-0.33$-0.27-22.22%Miss+43.1%
    Sep 23
    		$-0.95$-0.58-63.79%Miss-25.0%
    Jun 23
    		$-0.81$-0.83+2.41%Beat+10.0%
    Mar 23
    		$-0.88$-0.72-22.22%Miss+18.5%
    Dec 22
    		$-0.58$-0.80+27.50%Beat+3.3%
    Sep 22
    		$-0.76$-0.91+16.48%Beat+49.3%
    Jun 22
    		$-0.90$-0.90+0.00%Beat+57.1%
    Mar 22
    		$-1.08$-1.05-2.86%Miss+34.5%
    Dec 21
    		$-0.60N/A+52.76%Beat+0.0%
    Sep 21
    		$-1.50$-1.65+9.09%Beat+9.1%
    Jun 21
    		$-2.10$-1.60-31.25%Miss+12.5%
    Mar 21
    		$-1.65$-1.15-43.48%Miss+15.4%
    Dec 20
    		$-0.60$-1.05+42.86%Beat+88.9%
    Sep 20
    		$-1.65$-1.30-26.92%Miss-466.7%
    Jun 20
    		$-2.40$-3.07+21.82%Beat+48.4%
    Mar 20
    		$-1.95$-2.95+33.90%Beat+40.9%
    Dec 19
    		$-5.40$-2.40-125.00%Miss-350.0%
    Sep 19
    		$0.45N/A+118.75%Beat+123.1%
    Jun 19
    		$-4.65$-2.62-77.48%Miss+13.9%
    Mar 19
    		$-3.30$-4.35+24.14%Beat+58.5%
    Dec 18
    		$-1.20N/A+72.41%Beat-126.4%
    Sep 18
    		$-1.95$-3.22+39.44%Beat+45.8%
    Jun 18
    		$-5.40$-3.67-47.14%Miss-20.0%
    Mar 18
    		$-7.95$-3.45-130.43%Miss+3.6%
    Dec 17
    		$-0.53$-0.23-130.43%Miss+95.6%
    Sep 17
    		$-3.60$-3.75+4.00%Beat+87.7%
    Jun 17
    		$-4.50$-6.00+25.00%Beat-
    Mar 17
    		$-8.25$-5.25-57.14%Miss-
    Dec 16
    		$-12.00$-17.25+30.43%Beat-
    Sep 16
    		$-29.25$-15.75-85.71%Miss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$52.97
    SMA 20$52.89
    SMA 50$46.05
    SMA 200$52.23
    EMA 10$52.93
    EMA 20$52.17
    EMA 50$48.71
    EMA 200$50.75

    MACD

    Line: 1.47Signal: 1.95Hist: -0.48

    ADX

    ADX: 50.6+DI: 47.2-DI: 14.3

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down8.0
    PSAR$52.82

    Bollinger Bands

    Upper Band$53.08
    Lower Band$52.70
    %B Position73%(Middle)
    Band Width0.81

    RSI (14-Day)

    Overbought
    77.7

    Momentum Oscillators

    Stoch %K100.0
    Stoch %D98.6
    Williams %RN/A
    ROC (10d)0.2%
    Momentum0.09
    CCI (20d)104.2
    MFI (14d)85.3

    Volatility Measures

    ATR (14d)$0.38(0.7%)
    StdDev (20d)0.10
    Hist Vol1.1%(Low)

    Volume Flow

    VWAP$53.01
    OBV66.2M
    AD Line-9.8M
    CMF (20d)0.257

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol RatioN/A
    VWMA (20d)$52.88

    Pivot Points

    R3$53.01
    R2$53.01
    R1$53.01
    Pivot Point$53.01
    S1$53.01
    S2$53.01
    S3$53.01

    Advanced Oscillators

    TSI55.95
    Ultimate Osc58.3
    KST214.22

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$94.60M$91.73M$66.02M$32.66M$0$0$0$0$0$3.45M$0$0
    Cost of Revenue$1.20M$863,000$1.14M$696,000$0N/A$0$0$0$489,000$0$0
    Gross Profit$93.41M$90.87M$64.88M$31.96M$0N/A$0$0$0$2.96M$0$0
    Operating Expenses$62.13M$51.29M$42.77M$38.49M$45.74M$59.12M$80.21M$24.87M$23.48M$13.91M$10.38M$8.62M
    R&D$11.27M$9.56M$8.40M$9.15M$13.52M$21.49M$30.14M$12.34M$14.60M$8.69M$6.04M$5.14M
    SG&A$50.37M$40.88M$33.75M$28.24M$29.26M$37.30M$49.20M$10.89M$8.47M$4.14M$3.32M$3.17M
    Operating Income$31.28M$39.58M$22.11M$-6,525,000$-45,743,000$-59,116,000$-80,212,000$-24,868,000$-23,475,000$-13,910,000$-10,382,000$-8,623,000
    Interest Income$4.93M$5.13M$5.30M$3.19M$3.33M$3.37M$3.60M$3.01M$2.08M$2.14M$174,000$147,000
    Interest Expense$1.29M$1.35M$1.39M$1.38M$1.36M$231,000$0$0$0$0$479,000$0
    Income Before Tax$34.91M$43.36M$26.01M$-4,708,000$-43,773,000$-55,982,000$-76,616,000$-21,854,000$-21,398,000$-11,296,000$-10,861,000$-8,475,000
    Income Tax Expense$3.54M$0$0$0$0$0$0$0$0$0$0$0
    Net Income$31.38M$43.36M$26.01M$-4,708,000$-43,773,000$-55,982,000$-76,616,000$-21,854,000$-21,398,000$-11,296,000$-10,861,000$-8,475,000
    EBITDA$31.58M$38.90M$22.25M$-6,988,000$-46,211,000$-60,013,000$-81,621,000$-25,487,000$-23,458,000$-13,421,000$-10,545,000$-8,133,000
    EBIT$31.28M$39.58M$22.11M$-6,525,000$-45,743,000$-59,116,000$-80,212,000$-24,868,000$-23,475,000$-13,910,000$-11,035,000$-8,622,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLNO

    News

    Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ:SLNO) on behalf of investors who purchased securities prior to May 26, 2025. The investigation aims to determine if the company and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, with no cost incurred by investors as they operate on a contingency fee basis.

    ACCESS Newswire•8/7/26•
    Bearish

    Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ:SLNO) concerning alleged corporate wrongdoing. The firm is encouraging stockholders who purchased Soleno securities prior to May 26, 2025, and still hold them, to contact them to assist with the investigation. The investigation aims to recover investor capital and ensure corporate accountability.

    ACCESS Newswire•8/5/26•
    Bearish

    Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therap

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ: SLNO) on behalf of investors who purchased securities prior to May 26, 2025, and still hold them. The investigation focuses on whether Soleno and its officers or directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, noting that they represent investors on a contingency fee basis.

    The National Law Review•8/3/26•
    Somewhat-Bearish

    Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact

    Neurocrine Biosciences (NBIX) filed an amendment detailing the financial impact of its Soleno Therapeutics acquisition, including Soleno's 2025 and Q1 2026 financial results and pro forma combined statements. The acquisition adds VYKAT XR, valued at $2.23 billion, leading to significant amortization expenses, while pro forma revenues for 2025 reached $3.05 billion. The report also outlines a $1 billion revolving credit facility, which Neurocrine drew from and repaid shortly after closing.

    Stock Titan•8/1/26•
    Somewhat-Bullish

    Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

    Neurocrine Biosciences reported a 39% year-over-year increase in total second-quarter 2026 revenue, reaching $959 million, and raised its INGREZZA net sales guidance for the full year. The company completed the acquisition of Soleno Therapeutics in May 2026, adding VYKAT XR to its portfolio, and announced positive clinical data for CRENESSITY and VYKAT XR, while also detailing future clinical milestones for 2027.

    TradingView•7/30/26•
    Neutral

    Frequently Asked Questions About SLNO

    Does SLNO pay dividends?
    SLNO (SLNO) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In